# A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

> **NCT02944864** · PHASE1 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 53 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** TQ-B3395

## Key facts

- **NCT ID:** NCT02944864
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-13
- **Primary completion:** 2021-05-23
- **Final completion:** 2022-09-15
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Per sponsor request.
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944864, "A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02944864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*